NCT06981377 PRostate Cancer Plasma Integrative Multi-modal Evaluation
| NCT ID | NCT06981377 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Santa Chiara Hospital |
| Condition | Metastatic Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2019-05-07 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2019-05-07 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to develop PRIME (PRostate cancer plasma Integrative Multi-modal Evaluation) liquid biopsy test and to implement its use to query prospectively collected samples in advanced prostate cancer (PCa) clinical trials and/or clinical settings. In order to maximise the utility of liquid biopsies for advanced PCa, PRIME is focused on the development of novel computational and sequencing approaches that integrate multiple information from plasma circulating elements: i) cell free DNA (cfDNA) gene mutation data with accurate quantitation of cfDNA structural genomic changes, ii) cfDNA genomic profiling with cfDNA methylation status, and iii) the information provided by extracellular vesicles (EVs) and EV-associated cargo (including DNA, RNA and proteins).
Eligibility Criteria
Inclusion Criteria: * Diagnosis of prostate cancer * Eligible for prostate cancer pharmacological treatment * Given consent to study participation Exclusion Criteria: \- Histological diagnosis other than prostate cancer
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06981377 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06981377 currently recruiting?
Yes, NCT06981377 is actively recruiting participants. Contact the research team at orazio.caffo@apss.tn.it for enrollment information.
Where is the NCT06981377 trial being conducted?
This trial is being conducted at Meldola, Italy, Orbassano, Italy, Padova, Italy, Trento, Italy.
Who is sponsoring the NCT06981377 clinical trial?
NCT06981377 is sponsored by Santa Chiara Hospital. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.